MedTrace Logo

Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00023816 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced solid tumors or lymphoma.

Conditions

  • Lymphoma
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

carbendazim

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Lee S. Rosen, MD · Jonsson Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00023816 on ClinicalTrials.gov